Skip to main content
SP5007,798.99+0.65%DOW53,839.99+0.13%NASDAQ26,803.03+0.81%BTC$62,778.00-1.28%ETH$1,875.00-0.33%GOLD$4,407.10-0.30%OIL$81.46+0.26%
Smart Investors Daily
Sign InSign Up Free
CV

AMEX · CVM

CEL-SCI Corporation

Healthcare · Biotechnology

$1.49

Up+$0.01 (+0.68%)

Updated Aug 14, 2026, 11:06 AM

SID Score

3.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
44.87M
P/E ratio
-1.07
Dividend yield
0.00%
52-week range
$0.89 – $4.95
Volume
57.2K
Avg. volume
93.07K

Price performance

CVM price history

1M range · 21 trading sessions · Daily adjusted prices

CVM closed at $1.49 after 21 trading sessions, up 29.57% for the selected period.

Last close
$1.49
Period change
+29.57%
Period low
$1.14
Period high
$1.72
Daily close
View OHLC price history
CVM OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 13, 2026$1.48$1.49$1.45$1.4957.2K
Aug 12, 2026$1.51$1.54$1.45$1.48152.98K
Aug 11, 2026$1.47$1.5375$1.47$1.52103.76K
Aug 10, 2026$1.71$1.7468$1.46$1.49325.83K
Aug 7, 2026$1.63$1.7275$1.57$1.72249.46K
Aug 6, 2026$1.55$1.62$1.50$1.61268.66K
Aug 5, 2026$1.36$1.54$1.36$1.52404.42K
Aug 4, 2026$1.25$1.385$1.25$1.36269.89K
Aug 3, 2026$1.21$1.31$1.15$1.25668.36K
Jul 31, 2026$1.22$1.22$1.155$1.16165.58K
Jul 30, 2026$1.15$1.24$1.15$1.22131.67K
Jul 29, 2026$1.23$1.23$1.14$1.14151.92K
Jul 28, 2026$1.195$1.22$1.1593$1.20144.43K
Jul 27, 2026$1.18$1.2139$1.1506$1.18148.72K
Jul 24, 2026$1.22$1.22$1.16$1.18144.92K
Jul 23, 2026$1.24$1.24$1.19$1.19106.28K
Jul 22, 2026$1.22$1.27$1.1706$1.23193.89K
Jul 21, 2026$1.24$1.33$1.21$1.25155.43K
Jul 20, 2026$1.21$1.29$1.11$1.27425.88K
Jul 17, 2026$1.13$1.17$1.09$1.17455.34K
Jul 16, 2026$1.18$1.43$1.10$1.151.58M

Latest CVM news

The latest Smart Investors Daily articles mentioning CVM.

Stock researchCompany · Overview

CVM research

Overview

Company profile and research snapshot.

Company profile

CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
CVM recent ratings
DateFirmRatingTarget
Jul 12, 2023EF HuttonBuy—
Mar 9, 2023EF HuttonBuy—
Dec 29, 2022EF HuttonBuy—
Apr 7, 2022EF HuttonBuy—
Jan 13, 2020H.C. WainwrightBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Benzinga · Aug 4, 2026

CEL-SCI Announces Publication Of Its Study, 'A Novel Neoadjuvant Immunotherapy Confers Improved Overall Survival In Oral Cancer Patients With Low Tumor PD-L1 Expression: The IT-MATTERS Clinical Trial – Prognostic Role Of Tumor PD-L1 Expression' In Journal Oral Oncology

The published article identified low and zero (0%) PD-L1 expression and no lymph node involvement as biomarkers for selecting patients most likely to benefit from Multikine pre-surgery treatmentStudy concludes Multikine

Benzinga · Jul 13, 2026

CEL-SCI To Launch Phase 3 Confirmatory Study

Patient enrollment expected to commence at clinical centers in the U.S., Europe, Asia and later on in South AmericaThe 212-patient confirmatory study is powered at approximately 97% to confirm a previously observed 0.34

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By